ArticleJournal of clinical medicine2021
Clinical Characteristics of Patients with Post-Tuberculosis Bronchiectasis: Findings from the KMBARC Registry.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Secondary infections following tuberculosis: epidemiology, pathogenesis and clinical implications.Breathe (Sheffield, England) · 2026Review
- Sputum microbiology data and related clinical outcomes among adult Aboriginal Australians with bronchiectasis.Internal medicine journal · 2025Article
- Neutrophilic inflammation in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Incidence and Risk Factors of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Article
- Clinical Characteristics of Chronic Obstructive Pulmonary Disease according to Smoking Status.Tuberculosis and respiratory diseases · 2025Article
- Epidemiology of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Bronchiectasis Development in a Male Patient With a History of Tuberculosis: A Case Report.Cureus · 2024Article
- Post-tuberculosis Sequelae in Children.Indian journal of pediatrics · 2024Review
- Bronchiectasis in Asia: a review of current status and challenges.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Association between statin use and tuberculosis risk in patients with bronchiectasis: a retrospective population-based cohort study in Taiwan.BMJ open respiratory research · 2024Article
- Article
- Performance during the Glittre-ADL test between patients with and without post-tuberculosis bronchiectasis: A cross-sectional study.PloS one · 2023Article
- Non-cystic fibrosis bronchiectasis: A single-centre retrospective study in Johannesburg, South Africa.African journal of thoracic and critical care medicine · 2023Article
- Profile of patients with post-tuberculosis bronchiectasis in a tertiary care hospital in Brazil.Journal of clinical tuberculosis and other mycobacterial diseases · 2022Article
- Bronchiectasis in Adults: Aetiology and New Therapies.Journal of clinical medicine · 2022Article
- Clinical outcomes and prognostic factors of bronchiectasis rheumatoid overlap syndrome: A multi-institution cohort study.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
Abstract
The clinical characteristics of patients with post-tuberculosis (TB) bronchiectasis have not been well evaluated. We enrolled 598 patients with bronchiectasis who participated in the Korean prospective bronchiectasis registry and compared the characteristics of post-TB bronchiectasis (19.7%) with post-infectious (19.6%), idiopathic (40.8%), and other (19.9%) bronchiectasis. The patients with post-TB bronchiectasis had a lower body mass index, higher rate of chronic obstructive pulmonary disease, and lower rate of asthma than those in the other groups. The patients with post-TB bronchiectasis had more upper lobe involvement, more severe radiological extent, and worse lung function than those in the other groups. Long-acting muscarinic antagonist/long-acting ß agonist use and mucolytics were more commonly used in the patients with post-TB bronchiectasis than those in the other groups, while inhaled corticosteroid/long-acting ß agonist was less commonly used. There were no significant intergroup differences in bronchiectasis severity scores except for FACED, the number of exacerbations, and quality of life. Post-TB bronchiectasis is characterised by reduced lung function and higher rates of mucolytic use when compared with other bronchiectasis; thus, adequate bronchodilator use and airway clearance techniques may alleviate symptom burden in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.